Dr. Michael W. Pennington

Former President and Chief Executive Officer

(502) 266-8787

Dr. Michael Pennington joined Peptides International in December 2010 as Chief Technology Officer. On January 1, 2013, Dr. Pennington's role became that of President and Chief Executive Officer. After doctoral research at University of Florida, he joined the pharmaceutical industry in the Department of Biotechnology at Schering-Plough. He joined Bachem Biosciences in King of Prussia, PA as a Principle Scientist in the Peptide Chemistry department. Dr. Pennington served as the Group Director for Bachem Biosciences before being appointed as President and C.O.O., a positioned he maintained from 2000 – 2010. He built and directed an internationally recognized peptide chemistry team focused on producing complex peptides and toxins. Dr. Pennington was a member of Bachem Forschungausschuss, the International Research and Development from 2000 – 2010. He has extensive collaborations with both industrial and academic scientists and maintains an extramurally funded research program on several peptide toxins. He is a founder of Airmid Inc., a biotech venture company dedicated to advancing two of his discoveries into clinical development for autoimmune diseases. Dr. Pennington has been awarded four patents and over 85 peer reviewed scientific articles, and serves as an editor of International Journal of Peptide Research and Therapeutics and Current Peptide and Protein Letters. He holds a Bachelor of Chemistry degree from the University of North Carolina at Chapel Hill and a Ph.D. from University of Florida at Gainesville.

Contributed Articles

View All Blog Articles


We at Peptides International are delighted to begin our own Blog, “PepTalk”, dedicated to all aspects of peptide science.

A Recipe for Success

Solid-phase peptide synthesis requires the use of a stable polymer-based support from which the growing peptide chain is elaborated during all of the chemistry steps used to synthesize the peptide.

TLR2 Targeting

A nice survey of the Toll-like receptor-2 (TLR2), along with our new product intended to assist research the TLR2 receptor targeting vaccine programs.

Nav-igating the Channels

A navigational map to the voltage-gated sodium channels (VGSCor Navs), their sub-types and some of the toxins that block them, including Peptides International's latest release, GpTX-1.